|
|||||
|
|

Electronic components manufacturer CTS Corporation (NYSE:CTS) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 8% year on year to $143 million. The company’s full-year revenue guidance of $540 million at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $0.60 per share was 1.6% below analysts’ consensus estimates.
Is now the time to buy CTS? Find out in our full research report (it’s free for active Edge members).
CTS faced a challenging Q3, with the market reacting negatively to its results despite revenue growth outpacing Wall Street’s expectations. Management attributed the underperformance to a mix of end market trends, including strong gains in medical, aerospace and defense, and industrial segments, offset by weaker transportation demand. CEO Kieran O’Sullivan highlighted that, “diversified sales for the quarter were 59% of overall company revenue,” reflecting an ongoing strategic focus. Margins were pressured by an adverse tax impact and a reserve increase related to an environmental claim.
Looking forward, CTS’s guidance reflects optimism around diversified end markets but caution over persistent headwinds. Management expects continued strength in therapeutic medical products and aerospace and defense, with SyQwest’s naval contract wins as a positive indicator. However, CFO Ashish Agrawal warned that recent U.S. tax legislation will continue to weigh on earnings, and transportation markets remain mixed. O’Sullivan noted, “we are closely monitoring the tariff and geopolitical environment,” emphasizing that cost management and supply chain agility will be critical for stability.
Management attributed the quarter’s performance to robust growth in diversified end markets and the successful execution of its diversification strategy, even as transportation remained a drag and margin pressures persisted.
CTS expects future performance to hinge on continued growth in diversified end markets, new defense wins, and careful margin management amid ongoing tax and transportation challenges.
Looking ahead, the StockStory team will watch (1) whether medical therapeutics and aerospace and defense bookings continue their current momentum, (2) signs of stabilization or recovery in transportation end markets, especially commercial vehicles, and (3) the ongoing impact of U.S. tax legislation and environmental reserves on margins. Progress on SyQwest’s contract pipeline and adoption of new vehicle electronics platforms will also be critical signposts.
CTS currently trades at $40.51, down from $42.41 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free for active Edge members).
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| Oct-30 | |
| Oct-29 | |
| Oct-28 | |
| Oct-28 | |
| Oct-28 | |
| Oct-28 | |
| Oct-28 | |
| Oct-28 | |
| Oct-27 | |
| Oct-26 | |
| Oct-15 | |
| Oct-10 | |
| Oct-07 | |
| Sep-29 | |
| Sep-23 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite